Scholarlink

Purpose <p>We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribulin (E) vs. either docetaxel (DTX) or paclitaxel (PTX).</p> Methods <p>Patients with HER2+ locally advanced/metastatic breast cancer (LABC/MBC) were randomized to receive E or taxane (T)&#xa0;(physician’s choice of DTX or PTX; declared in advance at registration) in 21-day cycles, each combined with trastuzumab + pertuzumab. Survival outcomes, treatment patterns, antitumor efficacy, safety, and QoL were examined.</p> Results <p>The intention-to-treat (and safety) populations comprised 224 (224) patients who received E, 186 (184) who received DTX, and 36 (34) who received PTX. Baseline characteristics were balanced. Progression-free survival (E vs. DTX: 14.0 vs. 13.1 months; hazard ratio [HR], 0.94 [95% CI, 0.74–1.21]; E vs. PTX: 14.1 vs. 10.8 months; HR, 1.00 [95% CI, 0.58–1.73]) and overall survival (E vs. DTX: not reached [NR] vs. NR; E vs. PTX: 75.5 months vs. NR) were similar among the subgroups. Although the incidences of adverse events (AEs) were generally similar, peripheral sensory neuropathy was more frequent with PTX and less frequent with DTX, compared with E. Neutropenia tended to be more frequent with E. Median time to QoL deterioration was longer with E vs. DTX (7.8 vs. 4.7 months) and E vs. PTX (6.1 vs. 3.9 months).</p> Conclusions <p>This trial revealed comparable efficacy of E vs. either DTX or PTX, when combined with dual HER2 blockade as first-line treatment for HER2+ LABC/MBC. AEs were generally similar between the E and T subgroups. QoL was maintained for longer in the E subgroups vs. T subgroups.</p> Trial registration <p>ClinicalTrials.gov (NCT03264547; registered: 28 June 2017); University Hospital Medical Information Network (UMIN000027938; registered: 26 June 2017).</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD

  • 期刊论文

  • 发表日期：

    2026年7月8日

查看全文
  • Norikazu Masuda,
  • Shigehira Saji,
  • Yasuyuki Kojima,
  • Masahiro Kitada,
  • Hiroshi Tada,
  • Tsutomu Iwasa,
  • Kei Koizumi,
  • Tsuguo Iwatani,
  • Yasuaki Sagara,
  • Takashi Kuwayama,
  • Masafumi Shimoda,
  • Tatsunari Sasada,
  • Koichiro Tsugawa,
  • Yoshihiro Kawaguchi,
  • Akihiko Shimomura,
  • Takuhiro Yamaguchi,
  • Hiroki Hasegawa,
  • Shun Osaka,
  • Satoshi Morita,
  • Toshinari Yamashita

摘要

Purpose

We performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribulin (E) vs. either docetaxel (DTX) or paclitaxel (PTX).

Methods

Patients with HER2+ locally advanced/metastatic breast cancer (LABC/MBC) were randomized to receive E or taxane (T) (physician’s choice of DTX or PTX; declared in advance at registration) in 21-day cycles, each combined with trastuzumab + pertuzumab. Survival outcomes, treatment patterns, antitumor efficacy, safety, and QoL were examined.

Results

The intention-to-treat (and safety) populations comprised 224 (224) patients who received E, 186 (184) who received DTX, and 36 (34) who received PTX. Baseline characteristics were balanced. Progression-free survival (E vs. DTX: 14.0 vs. 13.1 months; hazard ratio [HR], 0.94 [95% CI, 0.74–1.21]; E vs. PTX: 14.1 vs. 10.8 months; HR, 1.00 [95% CI, 0.58–1.73]) and overall survival (E vs. DTX: not reached [NR] vs. NR; E vs. PTX: 75.5 months vs. NR) were similar among the subgroups. Although the incidences of adverse events (AEs) were generally similar, peripheral sensory neuropathy was more frequent with PTX and less frequent with DTX, compared with E. Neutropenia tended to be more frequent with E. Median time to QoL deterioration was longer with E vs. DTX (7.8 vs. 4.7 months) and E vs. PTX (6.1 vs. 3.9 months).

Conclusions

This trial revealed comparable efficacy of E vs. either DTX or PTX, when combined with dual HER2 blockade as first-line treatment for HER2+ LABC/MBC. AEs were generally similar between the E and T subgroups. QoL was maintained for longer in the E subgroups vs. T subgroups.

Trial registration

ClinicalTrials.gov (NCT03264547; registered: 28 June 2017); University Hospital Medical Information Network (UMIN000027938; registered: 26 June 2017).

Graphical Abstract